Members of the CARE™ Hematology Faculty recently attended the American Society of Hematology (ASH) conference held in San Diego, California, from December 1st to 4th, 2018. With a lot of exciting news that came out of ASH 2018 in Chronic Lymphocytic Leukemia (CLL), CARE™ Faculty members felt a deeper look at certain storylines that are anticipated to have an impact to how we currently treat in Canada was warranted.
Among the exciting data presented at ASH this year, there were three trials anticipated to have a significant impact on how front-line CLL is treated in Canada – ECOG 1912, ALLIANCE A041202, and iLLUMINATE (PCYC-1130). Given the practice-changing implications, this report provides a deeper look into these clinical trials with additional context and perspectives provided by CARE™ Faculty members Dr. Philip Kuruvilla (William Osler Health Center) and Dr. Matthew Kang (Joseph Brant Hospital Cancer Clinic).
This report is meant as a supplemental piece to the CARE™ Perspectives ASH 2018 Conference Report distributed earlier this year. For more information or to access additional CARE™ at ASH resources please click here.
This report is written in the language which it was presented. The content and graphics included have been selected from the respective presentations given during the ASH 2018 meeting. Additional perspectives are provided by the CARE™ Hematology Faculty. To view the full abstract content from ASH 2018 please visit: https://ash.confex.com/ash/2018/webprogram/start.html.